This article was originally published in RAJ Devices
Prescription warning for cosmetic lens suppliers in US
You may also be interested in...
The firm’s major product revenues bounced back from the pandemic-troubled second quarter, with Botox recovering as predicted.
The global health crisis has presented a chance for the industry to improve its reputation by highlighting the value of its R&D engines. Pharma execs and observers talk to Scrip about why they are optimistic about industry’s chance to regain public trust.
FDA advisory committee members said the trial population was too small and homogenous and did not establish that Neovasc’s Reducer effectively treats angina.